Skip to main content
Niagen Bioscience, Inc. logo

Niagen Bioscience, Inc. — Investor Relations & Filings

Ticker · NAGE ISIN · US1710774076 LEI · 529900OPI7B8JPXCVS70 US Manufacturing
Open in API
Filings indexed 954 across all filing types
Latest filing 2011-08-11 Interim / Quarterly Rep…
Country US United States of America
Listing US NAGE

About Niagen Bioscience, Inc.

https://www.niagenbioscience.com/

Niagen Bioscience, Inc. (formerly ChromaDex) is a bioscience company focused on the science of nicotinamide adenine dinucleotide (NAD+). The company aims to improve healthspan and support healthy aging by developing products that restore and optimize cellular NAD+ levels. Its core proprietary ingredient is Niagen®, a patented and clinically studied form of nicotinamide riboside (NR), a precursor to NAD+. Niagen® is the key component in the company's consumer dietary supplement brand, Tru Niagen®, and is also developed for the food, beverage, and pharmaceutical markets. The company's research is supported by numerous human clinical studies, a portfolio of over 50 owned and licensed patents, and collaborations with global research institutions.

Recent filings

Filing Released Lang Actions
PROSPECTUS SUPPLEMENT
Interim / Quarterly Report Classification · 100% confidence The document is titled 'FORM 10-Q' and is described as a 'QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934' for the quarterly period ended July 2, 2011. It contains detailed unaudited financial statements including balance sheets, statements of operations, stockholders' equity, cash flows, and notes to the financial statements. It also includes management's discussion and analysis of financial condition and results of operations. The length of the document is approximately 15,000 characters, indicating it is a full report rather than a brief announcement. The presence of actual financial data and analysis confirms it is a substantive quarterly financial report. Therefore, the document fits the definition of an Interim / Quarterly Report (IR).
2011-08-11 English
10-Q
Interim / Quarterly Report Q2 2011
2011-08-11 English
Director's Dealing 2011
Director's Dealing
2011-07-16 English
Regulatory Filings 2011
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filing with the SEC, dated July 13, 2011, reporting the entry into a material definitive agreement (a License Agreement with Cornell University). It is a current report disclosing a significant contract or business event, not a full financial report or earnings release. The text does not contain financial statements or detailed financial analysis, but rather a description of the agreement terms and obligations. This type of filing is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about a material contract and does not fit into other specific categories like Annual Report, Earnings Release, or M&A filings. The document length is short (3809 characters), and it is not an announcement of a report publication but the report itself of a material event.
2011-07-13 English
CHROMADEX 8K JUNE 14 2011
Investor Presentation Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated June 14, 2011. It specifically states that it includes an investor presentation made at a conference, with slides attached as Exhibit 99.1. The text emphasizes that the presentation is being furnished and not filed, and it is intended for investor relations purposes. There are no financial statements or detailed financial data included in the text itself, only a reference to the presentation slides. This matches the definition of an Investor Presentation (IP) filing type, which is a detailed presentation for investors focusing on financials, strategy, and market position. The document length is 3178 characters, which is relatively short but contains the presentation material as an exhibit, consistent with an IP filing rather than a report publication announcement or regulatory filing. Therefore, the classification is Investor Presentation (IP) with high confidence.
2011-06-14 English
Director's Dealing 2011
Director's Dealing
2011-06-03 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.